Yarbrough Capital LLC Buys Shares of 88,163 Cardiff Oncology, Inc. (NASDAQ:CRDF)

Yarbrough Capital LLC bought a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) in the 1st quarter, Holdings Channel reports. The institutional investor bought 88,163 shares of the company’s stock, valued at approximately $277,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Rhumbline Advisers boosted its position in shares of Cardiff Oncology by 24.0% during the 4th quarter. Rhumbline Advisers now owns 53,172 shares of the company’s stock worth $231,000 after acquiring an additional 10,290 shares in the last quarter. Callan Capital LLC lifted its stake in Cardiff Oncology by 11.1% during the fourth quarter. Callan Capital LLC now owns 101,575 shares of the company’s stock worth $441,000 after purchasing an additional 10,108 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Cardiff Oncology by 68.7% in the 4th quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company’s stock valued at $1,253,000 after purchasing an additional 117,514 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Cardiff Oncology in the 4th quarter valued at $56,000. Finally, HighTower Advisors LLC increased its stake in shares of Cardiff Oncology by 123.1% in the 4th quarter. HighTower Advisors LLC now owns 34,213 shares of the company’s stock valued at $148,000 after purchasing an additional 18,880 shares during the last quarter. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their price objective on Cardiff Oncology from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, May 9th.

Cardiff Oncology Trading Up 7.2%

CRDF stock opened at $3.88 on Friday. The firm has a 50-day moving average price of $2.90 and a 200-day moving average price of $3.47. Cardiff Oncology, Inc. has a 12 month low of $2.01 and a 12 month high of $5.64. The stock has a market capitalization of $258.12 million, a P/E ratio of -4.13 and a beta of 1.61.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.09 million. Cardiff Oncology had a negative return on equity of 73.97% and a negative net margin of 6,238.17%. As a group, equities analysts predict that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.